Results 31 to 40 of about 217,476 (395)

An indolent pancreatic ductal adenocarcinoma with psammoma bodies and a coincidental neuroendocrine tumor

Human Pathology: Case Reports, 2019
Pancreatic ductal adenocarcinoma is a very aggressive neoplasm with a low survival rate, comprising the majority of pancreatic malignancies. Psammoma bodies have rarely been reported in pancreatic ductal adenocarcinoma, and their clinicopathologic ...
Hongxing Gui, Christopher P. Julien, Suehyb G. Alkhatib, Michael A. Husson   +3 more
doaj   +1 more source

Collision of ductal adenocarcinoma and neuroendocrine tumor of the pancreas: a case report and review of the literature [PDF]

, 2017
Background: Simultaneous occurrence of exocrine and neuroendocrine tumors of the pancreas is very infrequent. We report a patient with an endocrine tumor in the pancreatic-duodenal area and extensive exocrine carcinoma involving the whole pancreas.
Blandamura, Stella, Da Dalt, Gianfranco, Merigliano, Stefano, Pozza, Gioia, Serafini, Simone, Sperti, Cosimo, Valmasoni, Michele   +6 more
core   +2 more sources

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

Nature Genetics, 2015
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival rate of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes capturing precise tumor-specific molecular information difficult.
Richard A. Moffitt, Raoud Marayati, Elizabeth L Flate, Keith E. Volmar, S. G. H. Loeza, K. Hoadley, N. Rashid, Lindsay A Williams, Samuel C Eaton, Alexander H Chung, Jadwiga K Smyla, Judy M. Anderson, Hong Jin Kim, D. Bentrem, M. Talamonti, C. Iacobuzio-Donahue, Michael A. Hollingsworth, Jen Jen Yeh   +17 more
semanticscholar   +1 more source

Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing

Frontiers in Immunology, 2023
N-4 cytidine acetylation (ac4C) is an epitranscriptome modification catalyzed by N-acetyltransferase 10 (NAT10) and is essential for cellular mRNA stability, rRNA biosynthesis, cell proliferation, and epithelial-mesenchymal transition (EMT).
Dong Xu, Kaige Huang, Yang Chen, Fei Yang, Cunbing Xia, Hongbao Yang   +5 more
doaj   +1 more source

Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use [PDF]

, 2018
Pancreatic ductal adenocarcinoma has the worst prognosis of any cancer. New adjuvant chemotherapies are urgently required, which are well tolerated by patients with unresectable cancers.
A Hwang, A Isakovic, A Jo, A Kim, A Somogyi, A Tomimoto, A Vazquez-Martin, A Woods, AD Morris, Andrew R. Hart, AT Nies, B Liu, CJ Bailey, CJ Bailey, CJ Currie, CM Ambe, D Iliopoulos, D Ish-Shalom, DG Hardie, DG Hardie, DG Hardie, EJ Brown, G Zhou, GG Graham, H Takane, HA Hirsch, I Tkac, IB Sahra, IN Alimova, J Muller, JPT Higgins, K Cusi, K Inoki, K Polyak, K Zhou, K Zhou, L-W Wang, LA Cantrell, LL Campbell, M Bodmer, M Cerullo, M Pollak, M Reni, M Zhou, MA Frouws, MA Tempero, ML Goalstone, MM Kozak, MN Cook, MR Owen, N Leeuwen van, N Sadeghi, Philip J. Broadhurst, R Chaiteerakij, RC Turner, RM Memmott, S Amin, S Kordes, S Singh, S Wullschleger, SA Hawley, SE Kahn, SH Lee, SW Yee, T Conroy, T Conroy, T Higurashi, VN Anisimov, X Huang, X-S Deng, Y Choi, Y Shi, Y Zhao, Y Zhuang   +73 more
core   +1 more source

MicroRNA co-expression networks exhibit increased complexity in pancreatic ductal compared to Vater’s papilla adenocarcinoma [PDF]

, 2017
iRNA expression abnormalities in adenocarcinoma arising from pancreatic ductal system (PDAC) and Vater’s papilla (PVAC) could be associated with distinctive pathologic features and clinical cancer behaviours.
Andriulli, Angelo, Biagini, Tommaso, Capocefalo, Daniele, Carella, Massimo, Copetti, Massimiliano, De Bonis, Antonio, Di Sebastiano, Pierluigi, Francesco Di Mola, Fabio, Fusilli, Caterina, Maiello, Evaristo, Mastrodonato, Nicola, Mazza, Tommaso, Pazienza, Valerio, Piepoli, Ada, Tavano, Francesca   +14 more
core   +1 more source

The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data

Scientific Reports, 2020
Survival data for pancreatic cancer are usually based on actuarial calculations and actual long-term survival rates are rarely reported. Here we use population-level data from the Surveillance, Epidemiology, and End Results program for patients with ...
Axel Bengtsson, R. Andersson, D. Ansari
semanticscholar   +1 more source

Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells

Nature Communications, 2021
Pancreatic ductal adenocarcinoma (PDAC) has a collagen-rich dense extracellular matrix (ECM) that promotes malignancy of cancer cells and presents a barrier for drug delivery.
Chenxi Tian, Ying Huang, K. Clauser, S. Rickelt, Allison N. Lau, S. Carr, M. V. Vander Heiden, R. Hynes   +7 more
semanticscholar   +1 more source

Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. [PDF]

, 2018
Expression of the chromatin-associated protein HMGA2 correlates with progression, metastasis and therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Hmga2 has also been identified as a marker of a transient subpopulation of PDAC cells that has
Chiou, Shin-Heng, Dorsch, Madeleine, Grüner, Barbara M, Koong, Albert C, Kozak, Margaret M, Kusch, Eva, Naranjo, Santiago, Winslow, Monte M   +7 more
core   +1 more source

IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.

Cancer Discovery, 2018
Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic stroma. Within the stroma, cancer-associated fibroblasts (CAF) secrete tropic factors
Giulia Biffi, Tobiloba E. Oni, Benjamin P. Spielman, Yuan Hao, Ela Elyada, Youngkyu Park, Jonathan Preall, D. Tuveson   +7 more
semanticscholar   +1 more source